SCHEMBL1732873

SCHEMBL1732873

O=C(O)C(Oc1cccc2[nH]c3ccccc3c12)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IMPDH2 P12268 1/20 0.44
IMPDH1 P20839 1/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
POLB P06746 1/20 0.43
ABCG2 Q9UNQ0 1/20 0.43
PPARG P37231 1/20 0.43
PPARA Q07869 1/20 0.43
ADRB2 P07550 2/20 0.43
DNM1 Q05193 1/20 0.43
LMNA P02545 1/20 0.42
CYP3A4 P08684 1/20 0.42
MAPT P10636 1/20 0.42
TLR4 O00206 2/20 0.42
ADRB1 P08588 1/20 0.41
ADRB3 P13945 1/20 0.41
KEAP1 Q14145 3/20 0.40
NFE2L2 Q16236 3/20 0.40
GABRP O00591 1/20 0.40
GABRD O14764 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1733165 0.83 KMT2A (0.54) IMPDH2IMPDH1KMT2AABCG2PPARG
SCHEMBL1731305 0.80 ADRB2 (0.47) IMPDH2IMPDH1KMT2AABCG2PPARG
SCHEMBL1732896 0.78 ADRB2 (0.46) IMPDH2IMPDH1MEN1KMT2APOLB
SCHEMBL1733321 0.76 PPARG (0.47) IMPDH2IMPDH1MEN1KMT2AABCG2
SCHEMBL1732953 0.75 PPARG (0.44) KMT2AABCG2PPARGPPARAADRB2
SCHEMBL12154504 0.74 ADRB2 (0.42) ABCG2PPARGPPARAADRB2DNM1
SCHEMBL1733266 0.73 ADRB3 (0.43) ABCG2PPARGADRB2DNM1LMNA
SCHEMBL17950801 0.72 KDM4E (0.58) IMPDH2IMPDH1MEN1KMT2APOLB
SCHEMBL1732912 0.71 TLR4 (0.54) KMT2APOLBABCG2PPARGADRB2
SCHEMBL1732433 0.70 KDM4E (0.60) IMPDH2IMPDH1KMT2AABCG2PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8329913-B2 Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof ZERIA PHARMACEUTICAL CO., LTD. (JP) 2012-12-11 US disclosed
US-8329913-B2 Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof ZERIA PHARMACEUTICAL CO., LTD. (JP) 2012-12-11 US disclosed
US-8329913-B2 Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof ZERIA PHARMACEUTICAL CO., LTD. (JP) 2012-12-11 US disclosed
EP-1852433-B1 CARBAZOLE DERIVATIVE, SOLVATE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ZERIA PHARM CO LTD (JP) 2011-11-23 EP disclosed
US-20100286210-A1 Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof ZERIA PHARMACEUTICAL CO., LTD. (JP) 2010-11-11 US disclosed
US-20100286210-A1 Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof ZERIA PHARMACEUTICAL CO., LTD. (JP) 2010-11-11 US disclosed
US-20100286210-A1 Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof ZERIA PHARMACEUTICAL CO., LTD. (JP) 2010-11-11 US disclosed
EP-1852433-A1 CARBAZOLE DERIVATIVE, SOLVATE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Zeria Pharmaceutical Co., Ltd. (JP) 2007-11-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286210-A1 Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof CEL, LIPC, CES1 IMPDH2 3649/4885IMPDH1 2839/4885MEN1 3363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.